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Abstract
Background: Although it has been realized that restrictive mitral valve annuloplasty (MVA) may re-
sult in clinically significant functional mitral stenosis (MS), it still cannot be predicted. The purpose of 
this study was to identify risk factors for clinically significant functional MS following restrictive MVA 
surgery for chronic ischemic mitral regurgitation (CIMR). 
Methods: One hundred and fourteen patients who underwent restrictive MVA with coronary artery 
bypass grafting (CABG) for treatment of CIMR were retrospectively reviewed. Clinically significant 
functional MS was defined as resting transmitral peak pressure gradient (PPG) ≥ 13 mmHg.
Results: During the follow-up period (range 6–12 months), 28 (24.56%) patients developed clinically 
significant functional MS. The PPG at follow-up was significantly higher than that measured in the 
early postoperative stage (3–5 days after surgery). Moreover, there was a linear correlation between the 
two measurements (r = 0.398, p < 0.001). Annuloplasty size ≤ 27 mm and early postoperative PPG  
≥ 7.4 mmHg could predict clinically significant functional MS at 6–12 months postoperatively. 
Conclusions: Chronic ischemic mitral regurgitation patients treated with restrictive MVA and CABG 
have significant increases in PPG postoperatively. Annuloplasty size ≤ 27 mm and early postopera-
tive PPG ≥ 7.4 mmHg can predict clinically significant functional MS at 6–12 months after surgery.  
(Cardiol J 2019; 26, 4: 350–359)
Key words: chronic ischemic mitral regurgitation, restrictive mitral valve annuloplasty, 
coronary artery bypass grafting, functional mitral stenosis, transmitral peak pressure 
gradient
Introduction
Chronic ischemic mitral regurgitation (CIMR) 
is a frequent complication of ischemic heart disease 
and is associated with poor outcomes. Restrictive 
mitral valve annuloplasty (MVA) combined with 
coronary artery bypass grafting (CABG) is a tra-
ditional procedure for the surgical management of 
CIMR [1, 2]. Although restrictive MVA can reduce 
the risk of recurrence of mitral regurgitation (MR), 
it is intuitive that it may cause functional mitral ste-
nosis, leading to higher transmitral peak pressure 
gradient (PPG) and pulmonary arterial pressure 
(PAP) and, indeed, several reports in literature 
support this concept [3–6]. Recent studies suggest 
that resting PPG is an independent predictor of 
increased systolic PAP during exercise, and that 
a PPG ≥ 13 mmHg is the best predictor of poor 
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performance on the 6-minute walk test (6MWT) 
distance [4–7]. What is more, reduced 6MWT dis-
tance powerfully predicts morbidity and mortality 
in patients with heart failure [5, 8].
Since functional mitral stenosis has great 
negative influence on postoperative outcome, it 
is vital to identify factors that can predict whether 
or not a patient will develop clinically significant 
functional mitral stenosis after restrictive MVA 
surgery. Therefore, the objective of the present 
study was to identify the risk factors for the de-
velopment of clinically significant functional mitral 
stenosis in CIMR patients undergoing restrictive 
MVA and CABG. In addition, this study attempts to 
throw light on measures that can be taken to avoid 
the development of clinically significant functional 
mitral stenosis.
Methods 
Patients and study design
This study was approved by the Human Re-
search Ethics Committee of the Fuwai Hospital and 
was performed in accordance with the Declaration 
of Helsinki and the approved guidelines. From 
November 2008 to October 2015, 257 consecu-
tive CIMR patients underwent restrictive MVA 
and CABG in Fuwai hospital. These patients 
were eligible for inclusion in the study. CIMR was 
defined by echocardiographic and coronary angio-
graphic findings according to accepted criteria, i.e., 
1) MR occurring more than 16 days after myocardial 
infarction; 2) ≥ 70% stenosis of at least one coro-
nary artery, with wall motion abnormalities of the 
corresponding left ventricular (LV) segment; and 
3) Type I/IIIb leaflet dysfunction according to the 
Carpentier classification [9].
From the initial cohort of 257 patients, 
143 were excluded for various reasons [9], i.e., 
1) Presence of aortic valve regurgitation or ste-
nosis, congenital valvular heart disease, infective 
endocarditis, or recurrent MR (i.e., postoperative 
MR ≥ 2+ at follow-up); or 2) Performance of other 
procedures, such as LV reconstruction/reshaping, 
partial band/pericardial annuloplasty, or procedures 
other than ring annuloplasty for mitral valve plasty. 
Thus, the final study cohort was comprised of 
114 patients.
Baseline patient characteristics, echocardiog-
raphy data, operative data, and surgical techniques 
were collected from the Division of Cardiovascular 
Surgery database and individual medical records. 
Patients were followed up through the internet or 
telephone interviews and outpatient department 
records. Oral informed consent was obtained from 
all patients via questionnaire. The echocardiogra-
phy findings and outcomes at 6–12 months after 
discharge were analyzed. Median follow-up was 
8 months (interquartile range 6–10 months). 
At the end of follow-up (May 31, 2016), the com-
pleteness of follow-up was 96.21%. All collected 
data were sent to a core lab (State Key Labora-
tory of Cardiovascular Disease, Beijing, China) 
for analysis.
Surgical technique
Restrictive MVA and CABG were performed 
by senior surgeons with special interest in mitral 
valve surgery. Both procedures were performed by 
median sternotomy. The ring size was determined 
by measurements of the intertrigonal distance and 
anterior leaflet height. A successful repair was 
defined as leaflet coaptation of ≥ 0.8 cm and MR 
≤ 1 and mitral valve area > 1.5 cm2 at transesopha-
geal echocardiography performed at the end of 
cardiopulmonary bypass. Complete revasculariza-
tion was achieved in all patients after CABG. All 
patients received the same perioperative care. 
Intraoperative transesophageal echocardiography 
was routinely used.
Three kinds of complete symmetric rings 
(Carpentier-Edwards Physio Annuloplasty Ring, 
Carpentier-Edwards Physio II Annuloplasty Ring, 
and Medtronic Duran AnCore Ring) were used 
in the present study. The prosthesis sizes were 
26 mm (n = 9), 27 mm (n = 29), 28 mm (n = 30), 
29 mm (n = 14), 30 mm (n = 15), 31 mm (n = 4), 
32 mm (n = 12), and 33 mm (n = 1).
Echocardiography
Echocardiographic measurements followed 
American Society of Echocardiography guide-
lines [10]. MR was classified as mild (grade 1+), 
moderate (grade 2+), or severe (grades 3+ and 
4+). Of the 114 patients, 110 suffered from MR 
of grades 3+, while 4 suffered from MR of grades 
4+. Two-dimensional and Doppler transthoracic 
echocardiography examinations were performed 
before operation, in the early postoperative stage 
(3–5 days postoperatively), and at follow-up 
(6–12 months postoperatively). Clinically sig-
nificant functional mitral stenosis was defined as 
resting PPG ≥ 13 mmHg [5].
Statistical analysis
Continuous and categorical variables were re-
ported as mean ± standard deviation and percent-
ages, respectively. The c2 test and the t test were 
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used to compare the preoperative characteristics 
between groups. Logistic regression was used to 
identify the independent predictors of PPG ≥ 13 
mmHg (i.e., clinically significant functional mitral 
stenosis) at follow-up. To reduce the chance of 
overfitting the models, models were fit “reduced” 
which contained only variables whose univariate 
tests of associations with outcome, based on t test 
or the c2 test, were < 0.10 for outcome of PPG ≥ 13 
mmHg at follow-up. This approach yielded a subset 
of 5 predictors (denoted with a asterisk in Tables 1 
and 2) from the original set of 40. Because this 
data set was too small and variety of annuloplasty 
great, to fit the model, the study population were 
classified into four groups according to the size of 
annuloplasty: 26–27 mm group (n = 38; 33.33%), 
28–29 mm group (n = 44; 38.60%), 30–31 mm 
group (n = 19; 16.67%), and 32–33 mm group 
(n = 13; 11.40%). Model-based probabilities were 
analyzed using receiver operating characteristic 
(ROC) curves. Area under the curve (AUC) sum-
marizes information about outcome included in the 
“predictor” set, with a value of 1 as the maximum. 
All reported p values are two-sided, and values of 
p < 0.05 were considered to indicate statistical sig-
nificance. All statistical analyses were performed 
by SPSS 13.0 software (SPSS, Inc., Chicago, IL) 
and Graph Pad Prism release 5 (Graph Pad Software 
Inc, La Jolla, Calif) statistical packages.
Results 
Comparison of early postoperative  
PPG vs. follow-up PPG
Follow-up PPG was significantly higher than 
early postoperative PPG (9.55 ± 4.74 mmHg vs. 
7.31 ± 2.72 mmHg; p < 0.001; Fig. 1A). There 
was linear correlation between the two (r = 0.398; 
p < 0.001); the relationship between the early post-
operative PPG (X) and PPG at follow-up (y) could 
be expressed as: Y = X × 0.637 + 4.716 (Fig. 1B).
Comparison of demographics and clinical 
features between stenosis and non-stenosis 
patients
There were no deaths during the first 
6 months. Between 6 and 12 months postoperatively, 
3 patients died. A large proportion (28/114 patients; 
24.56%) were diagnosed with clinically significant 
functional mitral stenosis (i.e., PPG ≥ 13 mmHg) 
at follow-up. Stenosis and non-stenosis patients 
had similar characteristics at baseline (Tables 1, 2). 
There was no significant difference between the 
two groups in grade of MR. The echocardiographic 
results showed that, compared with the non-ste-
nosis group, both the PPG in early postoperative 
stage and at follow-up, and the follow-up transmi-
tral mean gradient were significantly higher in the 
stenosis group (all p < 0.001). After adjustment 
for the diameter of the preoperative left atrium, 
the stenosis patients had significantly larger left 
atrial diameter than the non-stenosis patients 
at follow-up (p < 0.001). The stenosis patients 
also had significantly worse New York Heart As-
sociation (NYHA) functional class at follow-up 
(p = 0.002; Fig. 2A).
Predicting occurrence of clinically significant 
functional mitral stenosis at follow-up
In forward multiple stepwise regression analy-
ses, the size of annuloplasty (p = 0.021) and early 
postoperative PPG (p < 0.001) were independently 
associated with clinically significant functional mi-
tral stenosis at follow-up (Table 3). In ROC curve 
Figure 1. A. Comparison of early postoperative trans-
mitral peak pressure gradient (PPG) vs. follow-up PPG 
for the overall population; B. Relationship between 
early postoperative and follow-up PPG; X — PPG at 
early postoperative stage; Y — PPG at follow-up; SD — 
standard deviation.
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Table 1. Preoperative demographic and clinical data of non-stenosis and stenosis patients.
Variables Non-stenosis (n = 86) Stenosis (n = 28) P 
Age [years] 58.42 ± 8.24 59.63 ± 8.92 0.554
Sex (male) 77 (89.53%) 21 (75.00%) 0.062*
Body surface area [m2] 1.91 ± 0.16 1.92 ± 0.18 0.773
EUROscore 5.62 ± 1.21 5.57 ± 1.07 0.861
Diabetes 25 (29.07%) 6 (21.43%) 0.430
Hypertension 53 (61.63%) 17 (60.71%) 0.931
Hyperlipidemia 37 (43.02%) 10 (35.71%) 0.495
COPD 4 (4.65%) 1 (3.57%) 0.804
Carotid artery stenosis 4 (4.65%) 3 (10.71%) 0.273
History of PCI 5 (5.81%) 3 (10.71%) 0.399
History of heart failure 18 (20.93%) 3 (10.71%) 0.204
Atrial fibrillation 11 (12.79%) 3 (10.71%) 0.768
Aneurysm 7 (8.14%) 2 (7.14%) 0.864
Grade on CCS angina scale: 
Total 0.231
I 51 (59.30%) 18 (64.29%)
II 14 (16.28%) 4 (14.29%)
III 8 (9.30%) 5 (17.86%)
IV 13 (15.12%) 1 (3.57%)
NYHA class III or IV 48 (55.81%) 16 (57.14%) 0.902
Left main CAD 23 (26.74%) 7 (25.00%) 0.968
CABG/patient 2.89 ± 0.70 2.81 ± 0.79 0.624
Distal anastomoses: 0.751
1 4 (4.65%) 2 (7.14%)
2–4 70 (81.40%) 21 (75.00%)
> 4 12 (13.95%) 5 (17.86%)
Anastomoses/patient 3.52 ± 0.95 3.41 ± 1.08 0.594
LIMA 81 (94.19%) 23 (82.14%) 0.062*
ACC time 113.36 ± 38.05 105.11 ± 24.11 0.183
CPB time 158.84 ± 47.91 146.89 ± 32.99 0.146
IABP 2 (2.33%) 1 (3.57%) 0.729
Prosthesis size: 0.010*
26–27 mm 22 (25.58%) 16 (57.14%)
28–29 mm 36 (41.86%) 8 (28.57%)
30–31 mm 13 (15.12%) 2 (7.14%)
32–33 mm 15 (17.44%) 2 (7.14%)
Concomitant procedure:
Modified maze procedure 1 (1.16%) 1 (3.57%) 0.434
Tricuspid annuloplasty 6 (6.98%) 1 (3.57%) 0.491
Mechanical ventilation time [h] 25.98 ± 16.68 26.38 ± 22.03 0.920
ICU stay time [h] 67.30 ± 50.37 76.54 ± 56.22 0.446
*Indicates variables entered into logistic regression. Data are shown as mean ± standard deviation or number (percentage). COPD — chronic 
obstructive pulmonary disease; PCI — percutaneous coronary intervention; CCS — Canadian Cardiovascular Society; NYHA — New York 
Heart Association functional class; CAD — coronary artery disease; CABG — coronary artery bypass grafting; LIMA — left internal mammary 
artery; ACC — aortic cross-clamp; CPB — cardiopulmonary bypass; IABP — intra-aortic balloon pump; ICU — intensive care unit
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Table 3. Logistic regression analysis for outcome of clinically significant functional mitral stenosis.
Variable Univariable Stepwise multivariable
Odds ratio (95% CI) P Odds ratio (95% CI) P 
Sex 2.852 (0.950–8.561) 0.062
LIMA 0.284 (0.076–1.066) 0.062
Prosthesis size 0.708 (0.545–0.920) 0.010 0.714 (0.536–0.950) 0.021
Early postoperative PPG 1.399 (1.169–1.675) < 0.001 1.407 (1.164–1.701) < 0.001
Preoperative LAD 1.102 (1.015–1.198) 0.021
CI — confidence interval; LIMA — left internal mammary artery; PPG — transmitral peak pressure gradient; LAD — left atrial dimension
analysis, both the size of annuloplasty (AUC = 0.68; 
p = 0.005) and early postoperative PPG (AUC 
= 0.75; p < 0.001) could effectively predict clini-
cally significant functional mitral stenosis at follow-
up. Annuloplasty size of ≤ 27 mm (sensitivity 74%, 
specificity 57%) and early postoperative PPG of 
≥ 7.4 mmHg (sensitivity 71%, specificity 71%) 
could effectively separate patients who developed 
clinically significant functional mitral stenosis at 
follow-up from those who did not. Importantly, the 
combination of the two had the best performance 
(AUC = 0.80; p < 0.001; Fig. 3).
Comparison of demographics and clinical 
features between the 26–27 mm group and 
the 28–29 mm group
Having found that an annuloplasty size ≤ 27 mm 
could effectively predict the occurrence of clini-
Figure 2. A. Comparison of preoperative and follow-up New York Heart Association (NYHA) functional class of the 
stenosis patients and the non-stenosis patients. There was no significant difference in preoperative NYHA class, but 
the follow-up NYHA class was significantly higher in stenosis patients than in non-stenosis patients; B. Comparison 
of preoperative and follow-up NYHA class for patients with 26–27 mm and 28–29 mm prosthesis. There was no sig-
nificant difference in preoperative NYHA class, but the follow-up NYHA class was significantly higher in patients with 
the 26–27 mm prosthesis than in patients with the 28–29 mm prosthesis.
Figure 3. Receiver operating characteristic curve gener-
ated by the combination of the size of annuloplasty and 
early postoperative transmitral peak pressure gradient; 
AUC — area under the curve.
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cally significant functional mitral stenosis at fol-
low-up, we compared the clinical features of the 
26–27 mm group and the 28–28 mm group. The 
two groups had similar characteristics, including 
body surface area (BSA), at baseline (Tables 4, 5). 
There was no significant difference in early postop-
erative PPG or transmitral mean gradient between 
the two groups, but both the follow-up PPG and 
transmitral mean gradient were significantly higher 
in the 26–27 mm group (both p = 0.001). The 
intensive care unit (ICU) stay time was markedly 
longer for the 26–27 mm group than the 28–29 mm 
group. The left atrium of the 26–27 mm group 
was significantly larger, both at the early postop-
erative stage (p = 0.003) and at follow-up (p = 
= 0.030). Furthermore, although the distribution 
of NYHA functional class in the two groups was 
similar preoperatively, the NYHA functional class 
was significantly worse in the 26–27 mm group at 
follow-up (p = 0.007; Fig. 2B).
Discussion 
According to available research, this study is 
the first to compare mitral gradients at different 
postoperative stages in CIMR patients undergo-
Table 4. Preoperative demographic and clinical data for the 26–27 mm group and the 28–29 mm group.
Variables 26–27 mm (n = 38) 28–29 mm (n = 44) P 
Age [years] 60.42 ± 8.19 57.86 ± 9.33 0.194
Sex (male) 31 (81.58%) 39 (88.64%) 0.367
Body surface area [m2] 1.91 ± 0.15 1.87 ± 0.12 0.151
EUROscore 5.58 ± 1.22 5.73 ± 1.17 0.576
Diabetes 11 (28.95%) 12 (27.27%) 0.866
Hypertension 23 (60.53%) 24 (54.55%) 0.585
Hyperlipidemia 15 (39.47%) 19 (43.18%) 0.734
COPD 2 (5.26%) 2 (4.55%) 0.881
Carotid artery stenosis 2 (5.26%) 2 (4.55%) 0.881
History of PCI 3 (7.89%) 3 (6.82%) 0.852
History of heart failure 7 (18.42%) 7 (15.91%) 0.763
Atrial fibrillation 8 (21.05%) 4 (9.09%) 0.125
Aneurysm 4 (10.53%) 3 (6.82%) 0.549
Grade on CCS angina scale: 
No angina 13 (34.21%) 16 (36.36%) 0.839
Class III or IV 6 (15.79%) 7 (15.91%) 0.988
NYHA class III or IV 24 (63.16%) 22 (50.00%) 0.231
Left main CAD 12 (31.58%) 11 (25.00%) 0.470
Distal anastomoses: 0.186
1 2 (5.26%) 2 (4.55%)
2–4 27 (71.05%) 38 (88.64%)
> 4 9 (23.68%) 4 (6.82%)
Anastomoses/patient 3.58 ± 1.15 3.42 ± 0.79 0.475
Grafts/patient 2.87 ± 0.70 2.86 ± 0.77 0.962
LIMA 34 (89.47%) 39 (88.64%) 0.904
ACC time [min] 107.24 ± 21.94 104.50 ± 33.31 0.658
CPB time [min] 153.97 ± 32.94 145.91 ± 37.81 0.310
Mechanical ventilation time [h] 28.76 ± 23.88 26.56 ± 15.08 0.619
ICU stay time [h] 89.86 ± 71.45 56.27 ± 27.97 0.012
Data are shown as mean ± standard deviation or number (percentage). COPD — chronic obstructive pulmonary disease; PCI — percutaneous 
coronary intervention; CCS — Canadian Cardiovascular Society; NYHA — New York Heart Association functional class; CAD — coronary 
artery disease; CABG — coronary artery bypass graft; IABP — intra-aortic balloon pump; LIMA — left internal mammary artery; ACC — aortic 
cross-clamp; CPB — cardiopulmonary bypass; ICU — intensive care unit
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ing restrictive MVA and CABG. A major finding 
of this study was that follow-up PPG was signifi-
cantly higher than early postoperative stage PPG. 
Interestingly, Murashita et al. [11] showed that 
restrictive MVA for degenerative regurgitation 
resulted in small mitral valve gradients, which 
decreased with time after discharge. Transmitral 
gradients are determined by both transmitral flow 
and the severity of the intrinsic stenosis [4, 12]. 
Unless there is corresponding increase in mitral 
effective orifice area (EOA) [4], the improvement 
in LV diastolic function after CABG will result in 
higher mitral gradients [13].
Previous studies have demonstrated that when 
ischemic MR is treated by restrictive MVA, MR is 
often traded for mitral stenosis, which may out-
weigh the benefits of this procedure on the hemo-
dynamic and clinical outcomes [5]. The occurrence 
of functional mitral stenosis after restrictive MVA 
has not been well studied despite its relatively 
high incidence (9–54%) [8, 12, 14]. Importantly, 
recent findings show that PPG can independently 
predict elevated systolic PAP during exercise as 
well as reduced 6MWT distance [4–7], which is 
a powerful predictor of morbidity and mortality in 
patients with heart failure [5, 8]. Thus, elevated 
resting peak mitral gradients correlate well with 
functional mitral stenosis and could serve as a good 
predictor of poor functional capacity [5]. However, 
several studies have shown that transmitral gradi-
ents do not correlate with functional capacity and 
an elevated gradient should not be considered as 
detrimental to functional capacity. Rubino et al. [3] 
divided 125 consecutive patients into two groups 
according to mean transmitral gradient (Dp = 
5 mmHg) at predischarge echocardiography. They 
found that mild mitral stenosis did not affect 
echocardiographic, functional, or clinical outcomes 
[3]. In this regard, it should be noted that PPG 
correlated with functional capacity better than 
mitral mean gradient, and PPG ≥ 13 mmHg was 
the best predictor of reduced 6MWT distance [5]; 
furthermore, the induction of mild mitral stenosis 
did not affect functional and echocardiographic 
outcomes [3]. Bertrand et al. [12] concluded that 
an increased transmitral gradient in a patient with 
normal cardiac output might be acceptable and 
may have no impact on functional capacity. How-
ever, their study had several limitations, including 
a small study sample of only 23 patients, which 
might have led to type II statistical errors; in ad-
dition, the fact that not all patients with ischemic 
MR participated in the study might have introduced 
a selection bias [12].Ta
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Magne et al. [5] have shown that the best 
predictors of reduced 6MWT distance in restric-
tive MVA patients were PPG and mitral mean 
gradient, with PPG ≥ 13 mmHg being the best 
predictor of reduced 6MWT distance (sensitivity 
92%, specificity 82%). On the basis of this impor-
tant finding, the present study defined clinically 
significant functional mitral stenosis as PPG ≥ 13 
mmHg at follow-up. In the current study, although 
the stenosis and the non-stenosis patients had 
similar characteristics at baseline, the former had 
larger left atrial diameter and worse NYHA func-
tional class. Thus, the present findings confirmed 
Magne et al.’s [5] conclusion that PPG ≥ 13 mmHg 
at follow-up can contribute greatly to the diagnosis 
of clinically significant functional mitral stenosis.
Unlike in mitral valve replacement, the EOA of 
the mitral valve in patients undergoing restrictive 
MVA is influenced not only by the size of annulo-
plasty but also by the severity of subvalvular leaflet 
tethering [6, 15]. Therefore, we still cannot predict 
prosthesis–patient mismatch preoperatively by 
BSA and EOA. A recent study showed that use of 
smaller prostheses (26 mm) for degenerative MR 
might result in higher PPG and a larger left atrium 
[16]. In the present study, although the 26–27 mm 
group and the 28–29 mm group had similar char-
acteristics (including BSA) at baseline, the former 
had longer ICU stay, higher PPG at follow-up, and 
worse NYHA functional class. Thus, the results of 
the present study show that when BSA is ≥ 1.90 m2, 
 an annuloplasty of 26–27 mm size might result in 
functional mitral stenosis and poor functional ca-
pacity. Therefore, when the BSA is ≥ 1.90 m2, it is 
advisable to avoid annuloplasties that are ≤ 27 mm 
in size; in these cases, an annuloplasty of size no 
smaller than 28 mm or mitral valve replacement 
would be a better alternative. Adherence to this 
rule should help prevent the possibility of postop-
erative functional mitral stenosis. Furthermore, 
because the transmitral pressure gradient tends to 
increase postoperatively due to the improvement 
in LV function after CABG, a larger prosthesis 
should be chosen when the option is between two 
sizes of prosthesis.
Of note, this study showed that early postoper-
ative PPG ≥ 7.4 mmHg can predict the occurrence 
of clinically significant functional mitral stenosis at 
follow-up. Therefore, patients with early postop-
erative PPG ≥ 7.4 mmHg need special attention, 
as they may potentially suffer prosthesis–patient 
mismatch in the future and require treatment. 
Limitations of the study
There are still some limitations. This study 
reports retrospective data from a single center 
and is subject to all the limitations inherent to this 
design. In addition, the small study sample might 
have led to type II statistical errors. Another limita-
tion is that echocardiographic measurements, such 
as cardiac output and systolic PAP, were available 
only for a subset of patients. However, with detailed 
information about NYHA functional class, evaluation 
still found a correlation between PPG and functional 
capacity. As this is a retrospective study, there was 
a lack of detailed data as to the degree of tether-
ing for all patients. Of note, transmitral pressure 
gradient is a combination of all reasons that affect 
the transmitral flow including mitral valve tether-
ing. With details of transmitral pressure gradient, 
functional mitral stenosis at follow-up could be 
predicted effectively.
Conclusions
The present results demonstrate that post-
operative PPG increases significantly in CIMR 
patients undergoing restrictive MVA and CABG. 
To reduce the risk of occurrence of clinically sig-
nificant functional mitral stenosis, annuloplasties 
of ≤ 27 mm should be avoided in patients with BSA 
≥ 1.90 m2, and a larger prosthesis should be chosen 
when the option is between two sizes of prosthesis. 
Of note, patients with early postoperative PPG 
≥ 7.4 mmHg are at high risk of developing clini-
cally significant functional mitral stenosis. Further 
studies are needed to determine selection of an-
nuloplasties for patients with conditions other than 
CIMR to avoid functional mitral stenosis.
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